The Utility of Data Tokenization in Clinical Trials

With the growing rate of real-world data (RWD) sources and the evolution of data technologies, it is essential to understand the advantages and challenges tied to linked RWD. In a study conducted by Boehringer Ingelheim and Science 37, they showed nearly 90% overlap between trial patient cohort and real-world datasets, even with small trial populations.

Learn how tokenization enables:

• Connecting diverse data sources to your clinical trials
• Protecting personally identifiable information
• Earlier access to real-world data

See how Datavant can link data directly into clinical trials, providing the potential to validate real world populations prior to marketing authorization.